Combination of BRAF and MEK inhibition in BRAF V600E mutant low‐grade ganglioglioma. (27th January 2020)

• Record Type: Journal Article
• Authors: Yau, Wing Hing; Ameratunga, Malaka
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 45:Number 5(2020)
• Page Start: 1172
• Page End: 1174
• Publication Date: 2020-01-27
• Subjects: medication -- pharmacogenomics; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.13112
• Languages: English
• ISSNs: 0269-4727

Abstract

Abstract: What is known and objective: Post‐surgical management of low grade gangliogliomas is controversial with paucity of data for the use of chemotherapy. BRAF mutations are present in a number of glioma subtypes and offer an opportunity for treatment with targeted therapy. Case summary: A 32‐year‐old man with an unresectable, BRAF V600E mutant, WHO grade 1 ganglioglioma is commenced on combination BRAF and MEK inhibition (vemurafenib and cobimetinib). Partial radiological and clinical response was noted after 13 weeks of treatment. Treatment complication with grade 2 skin and liver toxicity was resolved with dose interruption and reduction. What is new and conclusion: Combination BRAF and MEK inhibition present a safe and feasible treatment strategy in unresectable BRAF V600E mutant low grade ganglioglioma. Abstract : Combination BRAF and MEK inhibition therapy for unresectable BRAF V600E mutant low grade ganglioglioma.